Načítá se...
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for th...
Uloženo v:
| Vydáno v: | Molecules |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6017514/ https://ncbi.nlm.nih.gov/pubmed/29498635 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules23030551 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|